Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
137,162,201
-
Number of holders
-
16
-
Total 13F shares, excl. options
-
1,863,743
-
Shares change
-
+95,239
-
Total reported value, excl. options
-
$2,590,935
-
Value change
-
+$131,895
-
Number of buys
-
6
-
Number of sells
-
-7
-
Price
-
$1.39
Significant Holders of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) as of Q2 2023
19 filings reported holding LUCD - Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share as of Q2 2023.
Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,863,743 shares
of 137,162,201 outstanding shares and own 1.4% of the company stock.
Largest 10 shareholders include LUMINUS MANAGEMENT LLC (878,378 shares), VANGUARD GROUP INC (319,833 shares), Nantahala Capital Management, LLC (199,074 shares), GEODE CAPITAL MANAGEMENT, LLC (143,465 shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (135,000 shares), CITADEL ADVISORS LLC (62,511 shares), Verition Fund Management LLC (36,166 shares), Geneos Wealth Management Inc. (33,850 shares), BlackRock Inc. (26,304 shares), and LPL Financial LLC (14,400 shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.